Cerivastatin side effects

List of side effects
Adverse events Post-marketing adverse event reports Concomitant therapy
 * Skeletal
 * Neurological
 * Hypersensitivity reactions
 * Gastrointestinal
 * Skin
 * Reproductive
 * Eye
 * Laboratory abnormalities
 * Body as a whole
 * Cardiovascular system
 * Digestive system
 * Hemolytic and lymphatic system
 * Hypersensitivity reaction
 * Nervous system
 * Musculoskeletal system
 * Respiratory system
 * Urogenital system
 * Special senses
 * Laboratory abnormalities (post-marketing)

Adverse events
The following effects have been reported with drugs in this class; not all effects listed below have necessarily been associated with cerivastatin therapy. Return to top

Skeletal
Myopathy, muscle cramps, rhabdomyolysis, arthralgias, myalgia. Return to top

Neurological
Dysfunction of certain cranial nerves (including alteration of taste, impairment of extraocular movement, facial paresis), tremor, dizziness, memory loss, vertigo, paresthesia, peripheral neuropathy, peripheral nerve palsy, anxiety, insomnia, depression, psychic disturbances. Return to top

Hypersensitivity reactions
An apparent hypersensitivity syndrome has been reported that included one or more of the following features: anaphylaxis, angioedema, lupus erythematosus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome. Return to top

Gastrointestinal
Pancreatitis, hepatitis, including chronic active hepatitis, cholestatic jaundice, fatty change in liver, cirrhosis, fulminant hepatic necrosis, and hepatoma; anorexia, vomiting. Return to top

Skin
Alopecia, pruritus. A variety of skin changes, (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails), have been reported. Return to top

Reproductive
Gynecomastia, loss of libido, erectile dysfunction. Return to top

Eye
Progression of cataracts (lens opacities), ophthalmoplegia. Return to top

Laboratory abnormalities
Elevated transaminases, creatine kinase, alkaline phosphatase, -glutamyl transpeptidase, and bilirubin; thyroid function abnormalities. Return to top

Post-marketing adverse event reports
The following events have been reported since market introduction. While these events were generally associated with the use of BAYCOL®, a casual relationship to the use of BAYCOL® cannot be readily determined due to the spontaneous nature of reporting of medical events, and the lack of controls. Return to top

Body as a whole
Asthenia, fever, headache, anorexia, abdominal pain, epistaxis, edema. Return to top

Cardiovascular system
Hypertension, angina pectoris. Return to top

Digestive system
Colitis, constipation, diarrhea, duodenal ulcer, dyspepsia, flatulance, gastrointestinal disorder, gastrointestinal hemorrhage, hepatitis, nausea. Return to top

Hemolytic and lymphatic system
Anemia, leukopenia. Return to top

Hypersensitivity reaction
Allergic reaction, anaphylactoid reaction, angioedema, urticaria. Return to top

Nervous system
Paralysis, somnolence. Return to top

Musculoskeletal system
Myalgia, myasthenia, myopathy, myositis, rhabdomyolysis, hypertonia, hyperkinesia. Return to top

Respiratory system
Cough increase. Return to top

Urogenital system
Acute renal failure secondary to myoglobinuria. Return to top

Special senses
Cataract specified, visual disturbance, blurred vision. Return to top

Laboratory abnormalities (post-marketing)
Amylase increase, elevated transaminases, laboratory tests abnormal, kidney function abnormal, creatine phosphokinase increase. Return to top

Concomitant therapy
In studies where cerivastatin sodium has been administered concomitantly with cholestyramine, no adverse reactions unique to this combination or in addition to those previously reported for this class of drugs were reported. Myopathy and rhabdomyolysis (with or without acute renal failure) have been reported when HMG-CoA reductase inhibitors are used in combination with immunosuppressive drugs, fibric acid derivatives, erythromycin, azole antifungals or lipid-lowering doses of nicotinic acid. Concomitant therapy with HMG-CoA reductase inhibitors and these agents is generally not recommended. Concurrent treatment with gemfibrozil is contraindicated. Return to top